ELCC 2023 | What is the risk of pneumonitis in patients with pulmonary fibrosis treated with ICIs?

Milica Kontic Jovanovic, MD, PhD, Clinical Center of Serbia, Belgrade, Serbia, discusses how immune checkpoint inhibitors (ICIs) carries a lower risk of pneumonitis in patients with pulmonary fibrosis compared to surgery, radiotherapy, or chemotherapy approaches. Dr Jovanovic continues by advocating that the most optimal line of therapy may consist of immunotherapy in combination with anti-fibrotic glucocorticoids. This interview took place at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.